Poseida Therapeutics (Poseida Therapeutics) Days Sales Outstanding

: 32.28 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Poseida Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $8.84 Mil. Poseida Therapeutics's Revenue for the three months ended in Dec. 2023 was $25.00 Mil. Hence, Poseida Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 32.28.

The historical rank and industry rank for Poseida Therapeutics's Days Sales Outstanding or its related term are showing as below:

PSTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.42 Med: 38.24 Max: 53.15
Current: 53.15

During the past 7 years, Poseida Therapeutics's highest Days Sales Outstanding was 53.15. The lowest was 25.42. And the median was 38.24.

PSTX's Days Sales Outstanding is ranked better than
66.22% of 888 companies
in the Biotechnology industry
Industry Median: 72.105 vs PSTX: 53.15

Poseida Therapeutics's Days Sales Outstanding declined from Dec. 2022 (215.87) to Dec. 2023 (32.28).

Poseida Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Poseida Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

25.42

51.05

Poseida Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															215.87	77.31	46.38	100.39	32.28

Competitive Comparison

For the Biotechnology subindustry, Poseida Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poseida Therapeutics Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Poseida Therapeutics's Days Sales Outstanding falls into.

Poseida Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Poseida Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (9.088	+	9.01)	/	2 )	/	64.703	*	365
=	9.049					/	64.703	*	365
=	51.05

Poseida Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (8.672	+	9.01)	/	2 )	/	24.995	*	365 / 4
=	8.841					/	24.995	*	365 / 4
=	32.28

Poseida Therapeutics (NAS:PSTX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Poseida Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics (Poseida Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (NAS:PSTX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

2RZ:Germany

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Executives

John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Luke Corning	director	614 DAVIS STREET, EVANSTON IL 60201
Marcea Bland Lloyd	director	9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Rafael Amado	director	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Kristin Yarema	officer: President, Cell Therapy	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Malin Life Sciences Holdings Ltd	10 percent owner	2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
Eric Ostertag	director, 10 percent owner, officer: Chief Executive Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Kerry D. Ingalls	officer: Chief Operating Officer	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Brent Warner	officer: President, Gene Therapy	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Matthew A. Spear	officer: Chief Medical Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Harry J Leonhardt	officer: GC & Chief Compliance Officer	C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
David Hirsch	director	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Sean Murphy	director, 10 percent owner	C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703